Sharing Our Perspective - Archive

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights Blog is where we share our perspective and challenge preconceptions to clear a new path forward.

Shipments of Opana® ER will end September 1

Optum Workers' Comp
| Jul 26, 2017

In an ongoing efforts to monitor the removal of Opana® ER from the marketplace as requested by the FDA earlier this summer, Endo International plc confirmed they will cease manufacturing and shipping Opana ER (oxymorphone hydrochloride extended-release) by September 1, 2017.1 A representative from Endo International did state, however, that while this product is being discontinued from their product line, Opana ER may still be dispensed by the pharmacy until all product has been depleted. This timeframe was chosen to minimize disruption in treatment to patients taking the medication while they and their doctor evaluate other treatment options. To that end, patients should discuss treatment options at their next office visit or as soon as possible. 

We will continue to monitor and provide updates as information is received. If you have any questions please contact your account manager, clinical liaison or our Clinical Services team at 877.275.7674 ext. 8612.


1. Endo Says Shipments of Opana ER will end Sept. 1  Accessed July 25, 2017.  

Stay informed by receiving latest updates

Do you have a question about a blog post?